Novogene, a leading global provider of genomic services and solutions, has entered into an agreement with Illumina to purchase ten additional NovaSeq™ X Plus instruments, Illumina’s latest next-generation sequencing platform. This announcement cements Novogene’s position as one of the leading global sequencing providers.

As an early adopter of the NovaSeq X Plus, Novogene deployed the platform across its laboratories in China, the United States and Europe from its launch in April 2023. By leveraging the platform’s high throughput, increased capacity and cost efficiency, Novogene has been able to provide sequencing at scale across a broad range of services to its global client base. This investment enables Novogene to optimize its regional service capabilities worldwide, ensuring consistent, high-quality, and cost-effective services for scientists around the world.

Susan Tousi, Chief Commercial Officer, Illumina, said: “We take immense pride in our collaboration with Novogene, a global leader in commercial services, as we strive to broaden the scope of genomics through our revolutionary NovaSeq X Plus. Our enduring partnership with Novogene has spanned over a decade, during which both companies have worked relentlessly to democratize access to genomics worldwide. We have utmost confidence in Novogene’s continued commitment to providing genomics researchers globally with reliable, swift, and cost-effective Next-Generation Sequencing (NGS) services.”

Novogene’s longstanding partnership with Illumina started when the company became one of the first users of Illumina’s high-throughput sequencing system, HiSeq X Ten. Over the last decade Novogene has consistently been among the first to adopt Illumina’s new platforms, from HiSeq 2000/2500/4000, to MiSeq, NextSeq 500, NovaSeq 6000, and now NovaSeq X Plus. The rapidly growing market for next generation sequencing, coupled with constant advances in technology, has led to a close collaboration between Novogene and Illumina. Novogene is one of Illumina’s premier global business partners.

Dr. Ruiqiang Li, Chief Executive Officer, Novogene, commented: “Throughout our journey, Illumina has remained a pivotal partner for Novogene. Over a decade of collaboration, we’ve witnessed remarkable growth together. Illumina’s industry leading technology provides the foundation for breakthroughs in cutting-edge research. Novogene, drawing upon its extensive project experience, translates and applies these innovations worldwide. Currently operating in over 90 countries across six continents, Novogene’s global presence is a testament to the strong alliance between our two companies, driving the industry forward and fostering continuous development.”

In recent years, Novogene has embraced the latest technologies and expanded the applications and services available on these platforms, including PacBio’s third-generation sequencer, Revio, and Thermo Fisher’s Orbitrap Astral high-resolution mass spectrometer. Deployed across multiple laboratories within Novogene’s global network, these cutting-edge instruments broaden the range of services and applications available to the global scientific community.

Novogene remains dedicated to its customer-centric approach and its commitment to collaborating with global leaders like Illumina to empower life science research. At Novogene we continue to strive to be your trusted genomics partner.